fulvestrant has been researched along with trelstar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, D | 1 |
| Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I | 1 |
2 other study(ies) available for fulvestrant and trelstar
| Article | Year |
|---|---|
New drugs 2003, part II.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Desogestrel; Drug Approval; Drug Combinations; Drug Therapy; Epoprostenol; Estradiol; Ethisterone; Filgrastim; Fondaparinux; Fulvestrant; Granulocyte Colony-Stimulating Factor; Humans; Norgestrel; Oximes; Polyethylene Glycols; Polysaccharides; Recombinant Proteins; Triptorelin Pamoate; United States; Vinyl Compounds | 2003 |
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms | 2003 |